Keyword Company EPIC/TIDM SEDOL/ISIN News     Price Announcements Fundamentals News Article RSS Renalytix AI PLC (RENX) Add to Alerts list    Print         Mail a friend Wednesday 01 April, 2020 Renalytix AI PLC   RNS Number : 3212I Renalytix AI PLC 01 April 2020     Renalytix AI plc

Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence  in vitro  diagnostics for kidney disease, announces  that further to  RNS Reach 2937H on 24 March 2020,  Boston Healthcare Associates has presented data on  KidneyIntelX™, the Company’s AI-enabled in

Download  full announcement Lombard Odier Asset Management Place of completion  London, United-Kingdom Date of completion  27/03/2020

Presentation   titled:  Evaluation of Payer Budget Impact Associated with the Use of Artificial Intelligence in vitro Diagnostic, KidneyIntelX™, to Modify DKD Progression Oral presentation accepted for  Late Breaking session  of the National Kidney Foundation Spring Clinical Meeting Accompanying

Download  full announcement Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence  in vitro  diagnostics for kidney disease, announces its unaudited interim results for the six months ended 31 December 2019, a period of considerable progress in advancing

Renalytix AI plc (LSE: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that it will release its interim results for the six months ended 31 December 2019, on Tuesday 3 March 2020. Investor briefing A briefing open to all investors will take

Download  full announcement Renalytix AI plc (LSE: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces it will be presenting at the Cowen 40th Annual Health Care Conference, which runs from the 1-4 March 2020, hosted at Boston Marriott Copley

Download  full announcement Utah issues CLIA Certificate of Registration to allow patient testing New laboratory enables five-fold test volume increase to support 2020 commercial goals Renalytix AI plc (LSE: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that that the national price for KidneyIntelX™ set by the Centers for Medicare and Medicaid Services ("CMS") became effective as of 1 January 2020.

Download  full announcement US National pricing of $950 effective as of January 1 st , 2020 Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that that the Centers for Medicare and Medicaid Services (“CMS”) has released